Skip to main content

Table 6 Clinical parameters

From: Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Parameters

Baseline

Week 14

Change

P value

HbA1c (NGSP, %)

7.8 ± 0.7 (184)

7.3 ± 0.8 (181)

− 0.6 ± 0.7 (178)

< 0.001

HbA1c (mmol/mol)

62.1 ± 7.5 (184)

55.9 ± 8.7 (181)

− 6.2 ± 7.5 (178)

< 0.001

Fasting plasma glucose (mg/dl)

156.2 ± 39.6 (136)

137.2 ± 29.9 (147)

− 18.5 ± 39.5 (126)

< 0.001

Body weight (kg)

82.5 ± 14.6 (175)

80.7 ± 14.8 (173)

− 2.3 ± 2.8 (160)

< 0.001

BMI (kg/m2)

30.0 ± 4.4 (175)

29.3 ± 4.4 (172)

− 0.8 ± 1.0 (160)

< 0.001

Abdominal circumference (cm)

100.0 ± 11.6 (184)

98.3 ± 11.1 (178)

− 1.7 ± 4.5 (175)

< 0.001

Body fat percentage (%)

33.5 ± 7.7 (172)

33.7 ± 7.9 (172)

− 0.4 ± 2.4 (156)

0.06

Body fat (kg)

27.8 ± 8.8 (172)

27.4 ± 9.1 (171)

− 1.0 ± 2.7 (156)

< 0.001

Lean body mass (kg)

54.8 ± 10.9 (172)

53.3 ± 10.8 (171)

− 1.3 ± 2.3 (156)

< 0.001

Muscle mass (kg)

51.8 ± 10.4 (172)

50.5 ± 10.3 (172)

− 1.2 ± 2.2 (156)

< 0.001

Body water (kg)

36.7 ± 6.3 (172)

35.8 ± 6.4 (172)

− 0.8 ± 1.9 (156)

< 0.001

Bone mass (kg)

3.0 ± 0.5 (172)

2.9 ± 0.5 (171)

− 0.1 ± 0.2 (156)

< 0.001

Basal metabolic rate (kcal)

1585.8 ± 296.2 (172)

1543.2 ± 292.4 (171)

− 41.5 ± 73.0 (156)

< 0.001

TC (mg/dl)

184.9 ± 33.1 (146)

185.9 ± 32.0 (158)

− 0.1 ± 24.9 (141)

0.94

HDL-C (mg/dl)

47.1 ± 11.1 (166)

47.9 ± 10.9 (169)

0.9 ± 6.3 (158)

0.08

LDL-C (mg/dl)

108.3 ± 29.8 (129)

108.5 ± 27.1 (141)

− 1.1 ± 22.0 (118)

0.59

TG (mg/dl)

135.0 [99.0, 178.0] (133)

127.0 [93.0, 174.0] (145)

0.0 [− 30.0, 21.0] (123)

0.35

AST (IU/l)

32.5 ± 18.4 (171)

27.4 ± 14.0 (167)

− 5.1 ± 12.9 (160)

< 0.001

ALT (IU/l)

46.0 ± 30.4 (171)

37.6 ± 26.2 (167)

− 8.4 ± 19.2 (161)

< 0.001

γGTP (IU/l)

43.0 [29.0, 69.0] (157)

33.0 [24.0, 56.0] (153)

− 6.0 [− 18.0, 0.0] (147)

< 0.001

Serum creatinine (mg/dl)

0.72 ± 0.19 (173)

0.75 ± 0.20 (168)

0.02 ± 0.09 (162)

0.001

Uric acid (mg/dl)

5.5 ± 1.5 (169)

5.1 ± 1.3 (174)

− 0.4 ± 0.8(162)

< 0.001

Amylase (IU/l)

62.2 ± 33.0 (116)

66.6 ± 33.8 (120)

3.3 ± 16.4 (104)

0.040

RBC (× 104/μl)

487.0 ± 47.5 (160)

509.5 ± 45.6 (161)

23.0 ± 25.3 (151)

< 0.001

WBC (/μl)

7211.7 ± 1760.1 (160)

7174.3 ± 1856.8 (161)

27.5 ± 1369.5 (151)

0.81

Hemoglobin (g/dl)

14.5 ± 1.6 (160)

15.1 ± 1.6 (161)

0.6 ± 0.8 (151)

< 0.001

Hematocrit (%)

43.5 ± 4.2 (160)

45.8 ± 4.5 (161)

2.4 ± 2.6 (151)

< 0.001

Platelet (× 104/μl)

24.3 ± 6.5 (160)

24.4 ± 6.4 (161)

0.1 ± 3.2 (151)

0.76

Urinary albumin/Cr (mg/g Cr)

14.9 [7.8, 32.4] (105)

16.0 [7.7, 34.5] (110)

0.3 [− 5.5, 7.0] (85)

0.64

Urinary albumin (mg/l)

16.6 [4.6, 47.6] (50)

13.3 [7.0, 39.6] (60)

− 2.2 [− 12.4, 0.7] (41)

0.07

Urinary creatinine (mg/dl)

129.0 ± 73.7 (48)

89.8 ± 47.3 (63)

− 33.2 ± 76.3 (42)

0.007

Systolic blood pressure (mmHg)

132.3 ± 14.1 (183)

129.8 ± 14.5 (181)

− 2.7 ± 13.7 (178)

0.011

Diastolic blood pressure (mmHg)

80.6 ± 11.9 (183)

79.0 ± 12.2 (181)

− 1.6 ± 10.4 (178)

0.047

  1. Data are shown as mean ± SD (n) with P values by one-sample t-test, or median [Q1, Q3] (n) with P values by Wilcoxon signed-rank test
  2. HbA1c glycosylated hemoglobin, NGSP national glycohemoglobin standardization program, BMI body mass index, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, TG triglyceride, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyl transpeptidase, RBC red blood cells, WBC white blood cells